ICI 204,636 (SEROQUEL™): A Dibenzothiazepine Atypical Antipsychotic. Review of Preclinical Pharmacology and Highlights of Phase II Clinical Trials

CNS Drug Reviews

Volumn 1, Issue 1, 1995, Pages 50-73

  Goldstein, Jeffrey M ^a   Arvanitis, Lisa A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

5 HT2 antagonist; antipsychotics; clinical trials; dopamine D 2 antagonist; ICI 204,636; pharmacology; SEROQUEL

Indexed keywords

EID: 84989453448     PISSN: 1080563X     EISSN: 15273458     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1995.tb00276.x     Document Type: Article

References (42)

1. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
2. 3H‐SCH23390, a selective D‐1 receptor antagonist ligand, in rat striatum
3. The electrophysiological pharmacology of midbrain dopaminergic systems
4. The effects of antipsychotic drugs on the firing rate of dopaminergic neurons: a reappraisal
5. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single unit activity
6. What makes a neuroleptic atypical
7. Dopamine, acetylcholine and GABA effects in acute dystonia in primates
8. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
9. Chronic amphetamine intoxication: behavioral model of psychosis
10. 3H‐spiroperidol
11. D‐2 dopamine antagonist‐like effects of SCH23390 on A9 and A10 dopamine neurons
12. Spontaneous activity of A9 and A10 dopamine neurons after acute and chronic administration of the selective D‐1 antagonist SCH23390
13. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity
14. SEROQUEL: electrophysiological profile of a potential atypical antipsychotic
15. 3H‐prazosin to rat brain alpha‐adrenergic receptors
16. 3H‐8‐hydroxy‐2‐(di‐n‐propylamino)tetralin binding to pre‐ and postsynaptic 5‐hydroxytryptamine sites in various regions of rat brain
17. A Multicentre, Double‐blind, Placebo‐controlled Comparison of Low and High Dosage Regimens of SEROQUEL in the Treatment of Hospitalised Patients with Acute Exacerbation of Chronic and Subchronic Schizophrenia
18. 3H‐rauwolscine binding to alpha‐2‐adrenoceptors sites in the lumbar spinal cord of the cat: comparison to such binding in the cat frontal cerebral cortex
19. Treatment of schizophrenia
20. Clozapine of the treatment‐resistant schizophrenic
21. A preliminary procedure for the evaluation of central nervous system depressants
22. The pharmacology of tardive dyskinesia
23. 2 receptor binding sites. Binding properties, brain distribution, and functional role
24. Understanding the mechanism of action of atypical antipsychotic drugs
25. Neuroleptic‐induced acute dyskinesias in squirrel monkeys: Correlation with propensity to cause extrapyramidal side effects
26. A Multicentre, Double‐blind, Controlled Comparison of SEROQUEL and Chlorpromazine in the Treatment of Hospitalised Patients with Acute Exacerbation of Subchronic and Chronic Schizophrenia
27. Central versus peripheral anticholinergic activity as assessed by two in vivo procedures in mice
28. Long‐term changes in the sensitivity of pre‐ and post‐synaptic dopamine receptors in mouse striatum evidenced by behavioral and biochemical studies
29. Enhancement of benzodiazepine and GABA binding by the novel anxiolytic tracazolate
30. A prospective study of clozapine in treatment‐resistant patients. I. Preliminary report
31. Clozapine increases rat serum prolactin levels
32. SEROQUEL: behavioral effects in conventional and novel tests for atypical antipsychotic drug
33. One month prevalence of mental disorders in the US: based on five epidemiologic catchment area (EGA) sites
34. Effects of certain tranquilizers on the level of homovanillic acid in the corpus striatum
35. Rapid automated analysis of biogenic amines and their metabolites using reverse‐phase high performance liquid chromatography with electrochemical detection
36. 3‐Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds
37. D‐1 dopamine receptor stimulation elevates plasma prolactin levels
38. SEROQUEL: biochemical profile of a potential atypical antipsychotic
39. Brain dopamine receptors
40. Movement disorders induced in monkeys by chronic haloperidol treatment
41. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons
42. Muscarinic cholinergic binding in rat brain